Neumora Therapeutics, Inc. NMRA 深 滬
已收盤 08-01 16:00:00 美东时间
1.56
-0.400
-20.41%
華盛通- 最 高1.92
- 今 開1.88
- 成交量 211.57万股
- 最 低 1.515
- 昨 收 1.96
- 總市值 2.53亿
- 52周最高 17.1874
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 0.611
- 委 比 30.28%
- 總股本 1.62亿
- 歷史最高 21.00
- 量 比 1.00
- 振 幅 20.66%
- 歷史最低 0.611
- 每 手 1
- 風險率 5.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
<p>Neumora Therapeutics, Inc. announced it will host a conference call and live webcast on August 6, 2025, at 4:30 p.m. ET to discuss its second quarter 2025 financial results and provide a business update. The event will be available on the Company’s website at www.neumoratx.com, with a replay archived for 30 days. Participants can register here in advance. Neumora is a clinical-stage biopharmaceutical company focused on developing innovative th...
07-23 11:00
瑞穗：核心新药NMRA-861销售有望达12亿美元 上调Neumora(NMRA.US)目标价至5美元
瑞穗分析师Graig Suvannavejh发表研报，将Neumora Therapeutics目标价从4美元上调至5美元，并维持“跑赢大盘”评级。
07-21 14:35
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Telomir Pharmaceuticals (NASDAQ:TELO) shares rose 90.1% to $2.3 during...
07-19 01:06
Mizuho Maintains Outperform on Neumora Therapeutics, Raises Price Target to $5
Mizuho analyst Graig Suvannavejh maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and raises the price target from $4 to $5.
07-16 20:19
Neumora Therapeutics Begins Phase 1 Clinical Trial Of NMRA-861, A Selective M4 Positive Allosteric Modulator For Schizophrenia
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profileNo convulsions observed in pre-clinical studies conducted in multiple species, including rabbits
07-09 19:08
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Neumora Therapeutics has initiated a Phase 1 clinical trial for NMRA-861, a novel M4 muscarinic receptor PAM, targeting schizophrenia and other neuropsychiatric disorders. NMRA-861 shows promise as a best-in-class treatment, with preclinical studies indicating safety, no convulsions, and potential for once-daily dosing. The trial aims to evaluate safety, tolerability, and pharmacokinetics in healthy adults and those with stable schizophrenia. Res...
07-09 11:00
美股大行评级 | 潜在涨幅158.9%！蒙特利尔银行上调Disc Medicine目标价至120美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1129333511617925121.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从112美元升至120美元</p> <p>• 巴克莱：维持Karyopharm Therapeutics(KPTI)"超配"评级，目标价从5美
05-14 08:48
Needham Reiterates Buy on Neumora Therapeutics, Maintains $5 Price Target
Needham analyst Ami Fadia reiterates Neumora Therapeutics (NASDAQ:NMRA) with a Buy and maintains $5 price target.
05-13 21:44
Neumora Therapeutics shares are trading higher. The company reported Q1 financial results.
Neumora Therapeutics shares are trading higher. The company reported Q1 financi...
05-13 20:00
